SSGJ-612 / 3SBio - LARVOL DELTA

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=87 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

New P2 trial • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

New P2 trial • Biliary Tract Cancer • Breast Cancer • Esophageal Cancer • Gastric Cancer • Oncology • Solid Tumor

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

New P1 trial • Oncology • Solid Tumor

Guojian's HER2 mAb approved for trials in China (GBI Health) - "China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc., (HKEX:1530) announced receipt of clinical trial approval from the National Medical Products Administration for its SSGJ-612 in advanced solid tumors. SSGJ-612 is touted as the first therapeutic macromolecular monoclonal antibody (mAb) to enter the clinics that derives from the HER2 receptor and antagonizes the extracellular domain III of HER2."

Non-US regulatory • Oncology • Solid Tumor